SCHEDULE: T. Rowe Price Discloses 0.1% Stake in Prothena Corp

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, disclosing a 0.1% beneficial ownership stake in Prothena Corp PLC as of June 30, 2025.

Summary

• T. Rowe Price Associates, Inc. reported beneficial ownership of 71,047 shares of Prothena Corp PLC common stock.
• This ownership represents 0.1% of Prothena Corp PLC's outstanding common stock.
• T. Rowe Price Associates, Inc. holds sole voting power and sole dispositive power over all 71,047 shares.
• This document is Amendment No. 6 to a Schedule 13G, indicating previous filings for this stake.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual, routine regulatory filing disclosing beneficial ownership, which inherently carries no positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

Not applicable as this filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing is a standard regulatory disclosure by an institutional investment adviser, T. Rowe Price Associates, Inc., detailing its passive beneficial ownership in Prothena Corp PLC. It reflects a routine portfolio holding rather than a strategic industry move or competitive action.

Stakeholder Impact

• Minimal impact on shareholders as it represents a routine, passive investment disclosure by an institutional investor, not indicating any change in company strategy or performance.

Key Dates

Keywords

Prothena Corp PLC, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing